DelveInsight’s, “Human Immunodeficiency Virus Type 1 (HIV-1) Infection Pipeline Insight 2023,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Human Immunodeficiency Virus Type 1 (HIV-1) Infection pipeline landscape. It covers the Human Immunodeficiency Virus Type 1 (HIV-1) Infection pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the Human Immunodeficiency Virus Type 1 (HIV-1) Infection Pipeline Report

• DelveInsight’s Human Immunodeficiency Virus Type 1 (HIV-1) Infection pipeline report depicts a robust space with 10+ active players working to develop 10+ pipeline therapies for Human Immunodeficiency Virus Type 1 (HIV-1) Infection treatment.
• The leading companies working in the Human Immunodeficiency Virus Type 1 (HIV-1) Infection Market include United BioPharma, Gilead sciences, Taimed Biologics, Merck Sharp & Dohme, Janssen Sciences, CytoDyn Biosciences, MacroGenics, and others.
• Promising Human Immunodeficiency Virus Type 1 (HIV-1) Infection Pipeline Therapies in the various stages of development include B/F/TAF, TDF/3TC/EFV, ISL, DOR, Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (FDC), Cabotegravir – Injectable Suspension (CAB LA), Rilpivirine – Injectable Suspension (RPV LA), MK-8591A, and others.
• October 2023: Merck Sharp & Dohme LLC announced a study of Phase 3 clinical trials for Islatravir and FTC/TDF. This study will evaluate whether oral islatravir (ISL) is effective in preventing Human Immunodeficiency Virus Type 1 (HIV-1) infection in women at high-risk for HIV-1 infection. The study will compare oral ISL taken once a month with standard-of-care medication for prevention of HIV-1 infection, emtricitabine/tenofovir disoproxil (FTC/TDF), taken once per day. The primary hypothesis is that oral ISL is more effective than FTC/TDF at reducing the incidence rate per year of confirmed HIV-1 infections.
• October 2023: Janssen Sciences Ireland UC announced a study of phase 3 clinical trials for Etravirine. The purpose of this study is to provide etravirine (ETR) through this trial until participants can be switched to locally available ETR-based treatment regimens (that is, commercially available and reimbursed, or accessible through another source [example, access program or government program]), or local standard of care, as appropriate. This is open label continued access trial for HIV-1 infected children/adolescents who have completed treatment in clinical (parent) trial with etravirine (ETR) sponsored by/in collaboration with Janssen Research & Development and who continue to benefit from use of ETR.
• October 2023: Gilead Sciences announced a study of Phase 1 clinical trials for GS-5894, B/F/TAF and GS-1720. The goal of this master clinical trial study is to learn how novel antiretrovirals (medicines that stop the virus from multiplying) affect the human immunodeficiency virus-1 (HIV-1) infection in people living with HIV (PWH). This umbrella study will begin with a substudy of GS-5894 (Substudy-01), and new substudies may be added in the future. Substudies evaluating additional study drugs will be added in a staggered manner when relevant nonclinical and/or clinical data become available.
• October 2023: MRC/UVRI and LSHTM Uganda Research Unit announced a study of phase 3 clinical trials for Cabotegravir/Rilpivirine and Antiretroviral. IMPALA is a randomized, open-label, multicenter, interventional study of 540 virologically suppressed HIV-1 infected adults who have a history of sub-optimal adherence to daily oral ART and/or engagement in HIV care. The study will seek to demonstrate non-inferior antiviral effectiveness of the 2-monthly long-acting injectable combination of cabotegravir/rilpivirine as compared to continuation of first line oral antiretroviral therapy. A Phase 3b Randomised, Multicentre, Open-label Study Evaluating the Effectiveness of Switching to Two-monthly Long-acting Injectable Cabotegravir and Rilpivirine From First-line Oral Antiretroviral Therapy in HIV-1 Positive Virologically Suppressed Adults With a History of, or at Risk of, Sub-optimal HIV Control in Sub-Saharan Africa.

 

Request a sample and discover the recent advances in Human Immunodeficiency Virus Type 1 (HIV-1) Infection Treatment Drugs @ Human Immunodeficiency Virus Type 1 (HIV-1) Infection Pipeline Report

 

In the Human Immunodeficiency Virus Type 1 (HIV-1) Infection pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Human Immunodeficiency Virus Type 1 (HIV-1) Infection collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Human Immunodeficiency Virus Type 1 (HIV-1) Infection Overview

HIV-1 is the most common type of Human Immunodeficiency Virus. It attacks the body’s immune system. The virus destroys CD4 cells. CD4 cells help the body to fight infections. HIV-1 can severely damage immune system and lead to Acquired Immune Deficiency Syndrome (AIDS). Infection with HIV type 1 (HIV-1) typically occurs across mucosal surfaces or by direct inoculation.

 

Find out more about Human Immunodeficiency Virus Type 1 (HIV-1) Infection Therapeutics Assessment @ Human Immunodeficiency Virus Type 1 (HIV-1) Infection Preclinical and Discovery Stage Products

 

Human Immunodeficiency Virus Type 1 (HIV-1) Infection Emerging Drugs Profile

• UB421: United BioPharma
• Islatravir (MK-8591): Merck Sharp & Dohme
• PRO140: CytoDyn Inc.

 

Human Immunodeficiency Virus Type 1 (HIV-1) Infection Pipeline Therapeutics Assessment

There are approx. 10+ key companies which are developing the therapies for Human Immunodeficiency Virus Type 1 (HIV-1) Infection. The Human Immunodeficiency Virus Type 1 (HIV-1) Infection companies which have their Human Immunodeficiency Virus Type 1 (HIV-1) Infection drug candidates in the most advanced stage, i.e. phase III include, United Biopharma.

 

DelveInsight’s Human Immunodeficiency Virus Type 1 (HIV-1) Infection pipeline report covers around 10+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

 

Human Immunodeficiency Virus Type 1 (HIV-1) Infection pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Intramuscular
• Subcutaneous
• Molecule Type

 

Human Immunodeficiency Virus Type 1 (HIV-1) Infection Pipeline Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Small molecule
• Product Type

 

Learn more about the emerging Human Immunodeficiency Virus Type 1 (HIV-1) Infection Pipeline Therapies @ Human Immunodeficiency Virus Type 1 (HIV-1) Infection Clinical Trials Assessment

 

Scope of the Human Immunodeficiency Virus Type 1 (HIV-1) Infection Pipeline Report

• Coverage- Global
• Human Immunodeficiency Virus Type 1 (HIV-1) Infection Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Human Immunodeficiency Virus Type 1 (HIV-1) Infection Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Human Immunodeficiency Virus Type 1 (HIV-1) Infection Companies- United BioPharma, Gilead sciences, Taimed Biologics, Merck Sharp & Dohme, Janssen Sciences, CytoDyn Biosciences, MacroGenics, and others.
• Human Immunodeficiency Virus Type 1 (HIV-1) Infection Pipeline Therapies- B/F/TAF, TDF/3TC/EFV, ISL, DOR, Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (FDC), Cabotegravir – Injectable Suspension (CAB LA), Rilpivirine – Injectable Suspension (RPV LA), MK-8591A, and others.

 

Dive deep into rich insights for new drugs for Human Immunodeficiency Virus Type 1 (HIV-1) Infection Treatment, Visit @ Human Immunodeficiency Virus Type 1 (HIV-1) Infection Market Drivers and Barriers, and Future Perspective

 

Table of Content

1. Introduction
2. Executive Summary
3. Human Immunodeficiency Virus Type 1 (HIV-1) Infection: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Human Immunodeficiency Virus Type 1 (HIV-1) Infection – DelveInsight’s Analytical Perspective
7. In-depth Commercial Assessment
8. Human Immunodeficiency Virus Type 1 (HIV-1) Infection Collaboration Deals
9. Late Stage Products (Phase III)
10. UB421: United BioPharma
11. Drug profiles in the detailed report…..
12. Mid Stage Products (Phase II)
13. PRO140: CytoDyn Inc.
14. Drug profiles in the detailed report…..
15. Early Stage Products (Phase I)
16. Drug Name: Company Name
17. Drug profiles in the detailed report…..
18. Inactive Products
19. Human Immunodeficiency Virus Type 1 (HIV-1) Infection Key Companies
20. Human Immunodeficiency Virus Type 1 (HIV-1) Infection Key Products
21. Human Immunodeficiency Virus Type 1 (HIV-1) Infection- Unmet Needs
22. Human Immunodeficiency Virus Type 1 (HIV-1) Infection- Market Drivers and Barriers
23. Human Immunodeficiency Virus Type 1 (HIV-1) Infection- Future Perspectives and Conclusion
24. Human Immunodeficiency Virus Type 1 (HIV-1) Infection Analyst Views
25. Human Immunodeficiency Virus Type 1 (HIV-1) Infection Key Companies
26. Appendix

 

For further information on the Human Immunodeficiency Virus Type 1 (HIV-1) Infection Pipeline therapeutics, reach out to Human Immunodeficiency Virus Type 1 (HIV-1) Infection Unmet Needs and Analyst Views

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/human-immunodeficiency-virus-type-1-hiv-1-market